None
Conditions
Interventions
The group of remimazolam:Induction with remimazolam
The group of remimazolam combined with alfentanil:Induction with remimazolam combined with 4 µg/kg alfentanil
Sponsors
The First Affiliated Hospital, Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age>= 65 and =< 80 years. 2. American Society of Anesthesiologists (ASA) Physical Status Classification of I to III. 3. Handgrip strength < 26 kg for males and < 18 kg for females. 4. Calf muscle thickness (MT) measured by ultrasound < 1.5 cm. 5. The patient and/or their legal guardian agrees to participate in the clinical trial and has provided written informed consent.
Exclusion criteria
Exclusion criteria: 1. Diagnosed with acute-phase Chronic Obstructive Pulmonary Disease (COPD) or currently suffering from other acute or chronic pulmonary diseases requiring long-term or intermittent oxygen therapy. 2. Presence of severe cardiac insufficiency (functional capacity 37.5° Celsius). 6. Known allergy to sedative drugs such as remimazolam besylate or propofol, or to materials used in the procedure (e.g., adhesive tape). 7. Scheduled for emergency surgery. 8. Currently participating in another clinical trial. 9. Deemed by the investigator as unsuitable for participation in this trial for any other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ED90; | — |
Secondary
| Measure | Time frame |
|---|---|
| MOAA/S;Motor response; | — |
Countries
China
Contacts
Public ContactFangping Bao
The First Affiliated Hospital, Zhejiang University School of Medicine
Outcome results
None listed